Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications

Abstract

Extensive effort has been devoted to the discovery, development, and validation of biomarkers for early disease diagnosis and prognosis as well as rapid evaluation of the response to therapeutic interventions. Genomic and transcriptomic profiling are well-established means to identify disease-associated biomarkers. However, analysis of disease-associated peptidomes can also identify novel peptide biomarkers or signatures that provide sensitive and specific diagnostic and prognostic information for specific malignant, chronic, and infectious diseases. Growing evidence also suggests that peptidomic changes in liquid biopsies may more effectively detect changes in disease pathophysiology than other molecular methods. Knowledge gained from peptide-based diagnostic, therapeutic, and imaging approaches has led to promising new theranostic applications that can increase their bioavailability in target tissues at reduced doses to decrease side effects and improve treatment responses. However, despite major advances, multiple factors can still affect the utility of peptidomic data. This review summarizes several remaining challenges that affect peptide biomarker discovery and their use as diagnostics, with a focus on technological advances that can improve the detection, identification, and monitoring of peptide biomarkers for personalized medicine.

Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects

“…Peptidomics is considered General neuroproteomics workflow for discovery of disease biomarkers. (83)(84)(85). The peptides' life cycle is controlled by different processes and events, primarily determined by proteases and opposed-regulated protease inhibitors (85).…”

Direct and Continuous Monitoring of Multicomponent Antibiotic Gentamicin in Blood at Single-Molecule Resolution

“…Renowned for its breakthroughs in DNA sequencing and protein analysis, − nanopore technology possesses advantages such as real-time and single-molecule detection, miniaturization, low-cost, and high throughput. − These advantages indicate its potential for point-of-care monitoring of small molecules. , Up to now, nanopore-based methods for small-molecule analysis have exhibited exceptional molecular resolution and sensitivity. , Besides, they markedly enhance the convenience of detecting biofluids, − diminishing the reliance on specialized laboratory environments . However, it is obvious that the majority of small molecule sensing strategies rely on nanopores with channel constriction diameters of 1 nm and above, including biological nanopores (α-HL, , MspA, , FraC, et al), as well as certain types of solid-state nanopores. , These nanopores often require additional modification or molecule labeling due to their large channel diameter when detecting small molecules, which necessitates advanced engineering skills and may potentially limit their capability for continuous monitoring.…”

A Novel Three-Point Localization Method for Bladder Volume Estimation

“…However, during this process, patients experience significant discomfort and an increased risk of urinary tract infections. Urinary hesitancy, urinary retention, and urinary incontinence are significant factors contributing to urinary tract diseases [ 3 , 4 ]. Hence, the early estimation of bladder volume is especially crucial, serving as an integral component in treating urinary system diseases and assessing treatment effectiveness.…”